Compare CUZ & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUZ | MIRM |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | CUZ | MIRM |
|---|---|---|
| Price | $27.12 | $91.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $31.09 | ★ $97.55 |
| AVG Volume (30 Days) | ★ 1.5M | 833.6K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 4.74% | N/A |
| EPS Growth | ★ 3.48 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $955,949,000.00 | $471,794,000.00 |
| Revenue This Year | $15.34 | $54.25 |
| Revenue Next Year | $3.15 | $21.09 |
| P/E Ratio | $77.80 | ★ N/A |
| Revenue Growth | 15.46 | ★ 53.66 |
| 52 Week Low | $24.07 | $36.88 |
| 52 Week High | $31.36 | $93.70 |
| Indicator | CUZ | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 72.63 |
| Support Level | $26.00 | $85.98 |
| Resistance Level | $27.23 | $91.80 |
| Average True Range (ATR) | 0.61 | 3.82 |
| MACD | 0.12 | 1.15 |
| Stochastic Oscillator | 95.98 | 88.20 |
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.